Medical device teams should automate first-pass architectural analysis, then keep human experts in charge of threat validation, mitigation selection, and risk acceptance. The goal is not to remove review rigor, but to make it repeatable across products and releases. This approach helps teams surface risks earlier, generate traceable evidence, and reduce late-stage rework while preserving quality system control.
Scaling design review without turning it into a compliance bottleneck
Medical device teams run into a familiar tension: security design reviews have to be rigorous enough to support regulatory quality systems, but manual review does not scale when product lines, software changes, and release cadence grow. The practical answer is to separate repeatable analysis from judgment-heavy decisions. Automated pre-screening can standardise what gets examined, while human review remains responsible for the issues that require clinical, safety, or regulatory context. That keeps the process auditable without making it slow or inconsistent. For a control-oriented view of this balance, the NIST Cybersecurity Framework 2.0 is useful because it frames security as an organisational capability rather than a one-off checklist.
What teams often miss is that scale is not just a tooling problem. If review criteria are not codified, two similar designs can receive different outcomes depending on who is in the room. In practice, many medical device teams discover that their review process has become harder to defend only after a late-stage design change forces them to reconstruct why a prior decision was accepted.
How the review flow should work across products and releases
A scalable design review process usually works best as a layered filter. The first layer is automated triage: inventory the assets, trust boundaries, data paths, external interfaces, update mechanisms, and privilege assumptions that can be extracted from architecture diagrams, requirements, and implementation metadata. This first pass is not there to decide whether the design is safe. It is there to produce a consistent, comparable packet for human reviewers and to flag where the review needs deeper attention.
The second layer is expert validation. Security, safety, systems, and regulatory reviewers should confirm whether the automated findings are meaningful in context, whether the threat model is complete enough, and whether the proposed mitigations are proportionate to the device’s intended use and risk profile. That is where teams should decide whether a control is truly effective, whether a compensating control is acceptable, or whether the issue requires redesign. For device programmes with broader governance obligations, the EU AI Act regulatory framework is a helpful reminder that design governance must stay accountable even when parts of the workflow are automated.
The third layer is evidence management. A scaled review process should retain the architecture inputs, the review outputs, the rationale for each material decision, and the approval trail. That record is what makes the process repeatable across product families and releases. If a team cannot show how a review outcome was reached, then the process may be operationally efficient but it is not regulatory-ready. Where the design touches security and privacy controls directly, the control structure in NIST SP 800-53 Rev 5 Security and Privacy Controls can help teams think in terms of traceable control objectives rather than ad hoc comments.
- Use automation to normalise inputs, not to approve risky designs.
- Route only materially significant findings to human reviewers.
- Record the reason each mitigation was accepted, deferred, or rejected.
- Keep review criteria stable enough to compare releases over time.
Where this approach breaks down is when the automation is treated as a substitute for expert judgment or when teams allow local exceptions to accumulate without a consistent approval path.
Where scaling creates pressure points in device programmes
Tighter standardisation often increases upfront process overhead, so organisations have to balance throughput against the need for defensible regulatory control.
One edge case is the platform or shared-component model. If multiple devices inherit the same architecture pattern, a single review artefact can be reused, but only if the assumptions behind that artefact still hold for each downstream product. Another edge case is the high-change release stream, where frequent software updates can outpace formal review unless the organisation sets clear thresholds for what qualifies as a material change. There is also a judgment call around low-risk changes that appear minor but alter authentication, logging, remote access, or update trust. Those changes often deserve more scrutiny than teams initially expect.
Guidance versus consensus matters here. There is broad agreement that automation should support review consistency, but not full agreement on how much of the decisioning can be encoded without weakening accountability. Medical device teams should treat that as a governance design question, not a tooling preference. The safest pattern is to automate the repeatable analysis and keep exception handling, mitigation sign-off, and risk acceptance under human control. That preserves regulatory defensibility while still making the review function scalable across the portfolio.
Practitioner takeaway: scale the workflow around evidence quality and decision traceability, not around the number of reviews completed, because regulatory control is lost when exceptions become informal and unrecoverable.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST CSF 2.0, CIS Controls v8 and NIST SP 800-63 set the technical controls, while DORA and NIS2 define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | GV.RM — Risk Management Strategy | Scalable reviews need an organisation-wide risk decision model. |
| Recommendation — Define a repeatable review threshold and escalation path for material design changes. | ||
| CIS Controls v8 | 16 — Application Software Security | Design reviews align to secure-by-design control expectations for software change. |
| Recommendation — Embed security review gates into the software development lifecycle and release approvals. | ||
| NIST SP 800-63 | 4 — Identity Assurance | Medical device designs often hinge on strong authentication and identity decisions. |
| Recommendation — Verify identity and authenticator assumptions before approving access-related design changes. | ||
| DORA | ICT third-party risk — ICT Third-Party Risk Management | Shared components and suppliers create reusable-review dependency risk. |
| Recommendation — Assess supplier and platform dependencies before reusing prior design review decisions. | ||
| NIS2 | Risk management measures — Risk management measures | Governed security reviews support controlled development and operational resilience. |
| Recommendation — Apply proportionate controls and documented approval for security-relevant design changes. | ||
Related resources from NHI Mgmt Group
- How should security teams implement AI-assisted security design reviews without losing control over quality and consistency?
- How should security teams automate user access reviews without losing control quality?
- How should security teams scale GenAI applications in production without losing reliability or control?
- How should security teams design AI SOC workflows for hands-free investigation and response without losing control?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 7, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
